Tharimmune logo

TharimmuneNASDAQ: THAR

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

12 January 2022

Next earnings report:

07 November 2024

Last dividends:

N/A

Next dividends:

N/A
$2.22 M
-95%vs. 3y high
6%vs. sector
-vs. 3y high
-vs. sector
-92%vs. 3y high
23%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | 16 min ago
$1.93-$0.14(-6.76%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

THAR Latest News

Tharimmune Announces Upcoming Conference Presentations
accesswire.com25 October 2024 Sentiment: POSITIVE

BRIDGEWATER, NJ / ACCESSWIRE / October 25, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces that management will be participating in two upcoming conferences. Nir Barak, M.D.

Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab
accesswire.com16 September 2024 Sentiment: POSITIVE

BRIDGEWATER, NJ and LONDON, UK / ACCESSWIRE / September 16, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today that it has entered into a definitive agreement with Intract Pharma to exclusively license INT-023/TH023, an oral anti-tumor necrosis factor-alpha (TNF-α) monoclonal antibody, infliximab. This strategic partnership aims to expand Tharimmune's therapeutic pipeline and reinforce its commitment to pioneering novel treatments for autoimmune diseases.

Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board
accesswire.com22 July 2024 Sentiment: POSITIVE

BRIDGEWATER, NJ / ACCESSWIRE / July 22, 2024 / Tharimmune, Inc . (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, today announced the appointment of David Jones, Professor of Liver Immunology at Newcastle University in England, to its Scientific Advisory Board (SAB).

Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor
accesswire.com17 July 2024 Sentiment: POSITIVE

BRIDGEWATER, NJ / ACCESSWIRE / July 17, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces the appointment of David H. Clarke as a Strategic Advisor to the Company's executive management team.

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
accesswire.com10 June 2024 Sentiment: POSITIVE

Pharmacokinetic profile of oral transmucosal delivery of TH104 was comparable to intravenous delivery of reference drug Positive safety/tolerability achieved with TH104 reporting a mild side-effect profile Planning for Phase 2 trial for moderate-to-severe chronic pruritus in primary biliary cholangitis (PBC) is ongoing and on track to initiate in 2024 BRIDGEWATER, NJ / ACCESSWIRE / June 10, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology, reports positive results from its Phase 1 clinical trial with TH104, a proprietary transmucosal buccal film embedded with the approved, active compound nalmefene that easily adheres inside of the mouth on the cheek and biodegrades within minutes. Results in healthy subjects demonstrated consistent pharmacokinetic (PK) profiles across buccal and intravenous routes of administration with a comparable safety and tolerability profile between routes of administration.

Why Is Tharimmune (THAR) Stock Moving Today?
investorplace.com24 May 2024 Sentiment: NEGATIVE

Tharimmune (NASDAQ: THAR ) stock is on the move Friday as investors prepare for the company's shares to undergo a reverse split when markets close today. Tharimmune is enacting a one-for-15 reverse stock split for THAR shares.

Tharimmune To Participate in Two Upcoming Investor Conferences in May
Accesswire30 April 2024 Sentiment: NEUTRAL

Tharimmune, Inc. (NASDAQ:THAR), a biotechnology company focused on inflammation & immunology treatments, shared that CEO Randy Milby will be presenting at the Planet MicroCap Showcase: VEGAS 2024 at the Paris Hotel & Casino in Las Vegas, Nevada in May. He will also be meeting with investors individually.

Tharimmune to Present at the Emerging Growth Conference on March 7, 2024
Accesswire05 March 2024 Sentiment: POSITIVE

Tharimmune invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference BRIDGEWATER, NJ / ACCESSWIRE / March 5, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation & immunology is pleased to announce that it has been invited to present at the Emerging Growth Conference on March 7th, 2024 The next Emerging Growth Conference is presenting on March 7, 2024. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's Management team in real time.

Tharimmune (THAR) Up on Positive Data From Pipeline Candidate
Zacks Investment Research28 November 2023 Sentiment: POSITIVE

Tharimmune (THAR) announces positive data from a phase I study on TH104 and the development timeline in chronic pruritis in primary biliary cholangitis indication.

Why Is Tharimmune (THAR) Stock Down 70% Today?
InvestorPlace28 November 2023 Sentiment: NEGATIVE

Tharimmune (NASDAQ: THAR ) stock is falling on Tuesday after the clinical-stage biotechnology company announced a public offering for its shares. That public offering has Tharimmune selling 10 million shares of THAR stock.

What type of business is Tharimmune?

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

What sector is Tharimmune in?

Tharimmune is in the Healthcare sector

What industry is Tharimmune in?

Tharimmune is in the Biotechnology industry

What country is Tharimmune from?

Tharimmune is headquartered in United States

When did Tharimmune go public?

Tharimmune initial public offering (IPO) was on 12 January 2022

What is Tharimmune website?

https://www.tharimmune.com

Is Tharimmune in the S&P 500?

No, Tharimmune is not included in the S&P 500 index

Is Tharimmune in the NASDAQ 100?

No, Tharimmune is not included in the NASDAQ 100 index

Is Tharimmune in the Dow Jones?

No, Tharimmune is not included in the Dow Jones index

When was Tharimmune the previous earnings report?

No data

When does Tharimmune earnings report?

The next expected earnings date for Tharimmune is 07 November 2024